Aoki K R, Guyer B
Allergan, Inc., Irvine, CA 92715, USA.
Eur J Neurol. 2001 Nov;8 Suppl 5:21-9. doi: 10.1046/j.1468-1331.2001.00035.x.
Botulinum toxin type A is an important therapeutic agent for the treatment of movement and other disorders. As the clinical uses of botulinum toxin type A expand, it is increasingly important to understand the biochemical and pharmacological actions of this toxin, as well as those of other botulinum toxin serotypes (B-G). Botulinum neurotoxin serotypes exhibit differences in neurotoxin complex protein size, percentage of neurotoxin in the activated or nicked form, intracellular protein target, and potency. These properties differ even between preparations that contain the same botulinum toxin serotype due to variations in product formulations. As demonstrated in preclinical and clinical studies, these differences result in a unique combination of efficacy, duration of action, safety, and antigenic potential for each botulinum neurotoxin preparation.
A型肉毒杆菌毒素是治疗运动障碍和其他疾病的重要治疗药物。随着A型肉毒杆菌毒素临床应用的扩大,了解这种毒素以及其他肉毒杆菌毒素血清型(B - G)的生化和药理作用变得越来越重要。肉毒杆菌神经毒素血清型在神经毒素复合蛋白大小、活化或切割形式的神经毒素百分比、细胞内蛋白靶点和效力方面存在差异。由于产品配方的不同,即使是含有相同肉毒杆菌毒素血清型的制剂,这些特性也有所不同。正如临床前和临床研究所示,这些差异导致每种肉毒杆菌神经毒素制剂在疗效、作用持续时间、安全性和抗原潜力方面具有独特的组合。